Every 8-K that Metagenomi Therapeutics, Inc (MGX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MGX filings page.
Metagenomi Therapeutics, Inc. reported second quarter 2026 results and business updates, highlighting progress on its lead in vivo genome editing program MGX-001 for hemophilia A. IND-enabling studies are expected to be completed by the end of the third quarter of 2026, with an IND filing planned for the fourth quarter of 2026 and, subject to regulatory clearance, clinical trial initiation in 2027.
Cash, cash equivalents and available-for-sale marketable securities totaled $120.7 million as of June 30, 2026, and the company anticipates this cash runway will support operations through the fourth quarter of 2027. For the quarter, collaboration revenue was $(0.257) million, R&D expenses were $22.5 million, G&A expenses were $6.0 million, and net loss was $27.5 million, or $(0.73) per share.
Second quarter updates also noted that two Metagenomi posters, including one with extensive non-human primate data supporting MGX-001, received Top Poster Awards at the 2026 ISTH Congress. The company continues to evaluate additional disease indications for its large gene integration system for protein replacement via gene insertion.
Metagenomi Therapeutics, Inc. reported that Brian C. Thomas, Ph.D. resigned from its board of directors effective June 9, 2026, and the company stated his resignation was not due to any disagreement over operations, policies or practices. On the same date, Metagenomi held its 2026 annual stockholder meeting by virtual webcast. A quorum was established with 19,116,207 shares present or represented by proxy out of 37,647,057 shares outstanding and entitled to vote as of the April 13, 2026 record date. Stockholders elected Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A. as Class II directors to serve until the 2029 annual meeting, and ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Metagenomi Therapeutics reported first quarter 2026 results and pipeline progress. Cash, cash equivalents and available-for-sale marketable securities were $140.2 million as of March 31, 2026, and management anticipates this cash runway will support operations through the fourth quarter of 2027.
For the quarter, collaboration revenue was $1.25 million compared with $4.13 million a year earlier. Research and development expenses were $19.3 million versus $25.1 million, and general and administrative expenses were $6.5 million versus $6.8 million. Net loss was $23.1 million, or $0.61 per share, compared with a net loss of $25.0 million, or $0.68 per share, in the prior-year period.
The company highlighted continued progress for MGX-001, its lead hemophilia A program, which it expects to submit for regulatory review, including an IND, in the fourth quarter of 2026, with first-in-human studies planned for 2027. Metagenomi also referenced a publication in Nature Structural & Molecular Biology showcasing its compact CRISPR nuclease MG119-28 and reiterated its strategy to apply its in vivo genome editing platform to hemophilia A and additional genetic and cardiometabolic indications.
Metagenomi Therapeutics, Inc. reported full year 2025 results alongside key pipeline updates. The company ended December 31, 2025 with $160.8 million in cash, cash equivalents and marketable securities and expects this to fund operations through the fourth quarter of 2027.
Collaboration revenue was $25.2 million for 2025, while research and development expenses were $94.4 million and general and administrative expenses were $26.8 million. Net loss was $87.9 million, or $2.36 per basic and diluted share, on 37.3 million weighted average shares outstanding.
Operationally, the company completed a pre-IND meeting for its lead hemophilia A program MGX-001 after preclinical data in non-human primates showed curative FVIII activity, and it remains on track for a global regulatory submission, including an IND in the fourth quarter of 2026. It also reported in vivo proof-of-concept for Antithrombin (AT-III) Deficiency, advanced cardiometabolic collaborations with Ionis around APOC3, and completed a corporate name change to Metagenomi Therapeutics, Inc.
Metagenomi, Inc. has changed its corporate name to Metagenomi Therapeutics, Inc., effective 12:01 a.m. Pacific Time on January 12, 2026, through a certificate of amendment to its charter approved by the board under Delaware law. The change does not affect stockholder rights.
The board also amended and restated the company’s bylaws solely to reflect the new name, with no other changes. The company’s common stock will continue to trade on the Nasdaq Global Select Market under the symbol MGX, and the CUSIP number for the common stock will remain the same. A press release and a January 2026 corporate presentation related to the name change and business updates were furnished as exhibits.
Metagenomi, Inc. (MGX) filed an 8‑K announcing it furnished a press release with financial results for the quarter ended September 30, 2025 and additional business updates. The company also furnished a separate press release reporting positive dose range finding data from its MGX-001 hemophilia A program, and made its November 2025 corporate presentation available. These materials are furnished, not filed, under the Exchange Act.
Included exhibits are: 99.1 (earnings press release dated November 11, 2025), 99.2 (MGX-001 program update press release dated November 11, 2025), 99.3 (corporate presentation dated November 2025), and 104 (cover page Inline XBRL).
Metagenomi, Inc. announced its financial results for the quarter ended June 30, 2025 and provided additional business updates. The company furnished a press release and a corporate presentation as Exhibits 99.1 and 99.2 to this Current Report; these exhibits are furnished rather than filed and are not incorporated by reference except as expressly stated in a future filing. The report confirms the company’s common stock trades under the ticker MGX on the Nasdaq Global Select Market and indicates Metagenomi qualifies as an emerging growth company. No financial metrics or operational details are included in the body of this filing.